TURNING POINT THERAPEUTICS, INC. financial statements (2021 and earlier)

Company profile

Business Address 10628 SCIENCE CENTER DRIVE, SUITE 200
SAN DIEGO, CA 92121
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
3/31/2020
Q1
12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:1,12271071038040642379
Cash and cash equivalents554312471304817279
Short-term investments568399240351361251 
Other undisclosed cash, cash equivalents, and short-term investments(1)(1)(1)(1)(3)(0) 
Other undisclosed current assets989996176
Total current assets:1,131718719389415429255
Noncurrent Assets
Operating lease, right-of-use asset34444  
Property, plant and equipment3333321
Other noncurrent assets00     
Other undisclosed noncurrent assets  00051
Total noncurrent assets:6677772
TOTAL ASSETS:1,137725725396422436257
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities141055986
Accounts payable5512244
Employee-related liabilities9643742
Debt   11  
Other liabilities0000000
Other undisclosed current liabilities111065442
Total current liabilities:2420111114128
Noncurrent Liabilities
Long-term debt and lease obligation23334  
Operating lease, liability23334  
Liabilities, other than long-term debt      0
Other liabilities      0
Total noncurrent liabilities:26634 0
Total liabilities:2926181518128
Stockholders' equity
Stockholders' equity attributable to parent1,110702711382404421248
Common stock0000000
Additional paid in capital1,390934925565527522329
Accumulated other comprehensive income (loss)001(0)000
Accumulated deficit(280)(233)(215)(184)(123)(102)(81)
Total stockholders' equity:1,110702711382404421248
Other undisclosed liabilities and equity(2)(3)(3)  41
TOTAL LIABILITIES AND EQUITY:1,137725725396422436257

Income statement (P&L) ($ in millions)

12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
3/31/2020
Q1
12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
Other operating income1112   
Gross profit: 2512   
Operating expenses(48)(44)(33)(63)(23)(22)(18)
Other undisclosed operating loss  (1)(2)   
Operating loss:(48)(19)(33)(63)(23)(22)(18)
Net loss:(48)(19)(33)(63)(23)(22)(18)
Other undisclosed net income attributable to parent1112221
Net loss available to common stockholders, diluted:(47)(18)(31)(61)(21)(20)(17)

Comprehensive Income ($ in millions)

12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
3/31/2020
Q1
12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
Net loss:(48)(19)(33)(63)(23)(22)(18)
Other comprehensive income (loss) (1)1(0) (0)0
Other undisclosed comprehensive income (loss)(0)   0  
Comprehensive loss:(48)(19)(32)(63)(23)(22)(18)
Other undisclosed comprehensive income, net of tax, attributable to parent0112221
Comprehensive loss, net of tax, attributable to parent:(48)(18)(30)(61)(21)(21)(17)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: